Soybean Oil in Nifedipine-Loaded Nanostructured Lipid Carriers: Enhancing Drug Loading and Release
Issued Date
2025-01-01
Resource Type
ISSN
25868195
eISSN
25868470
Scopus ID
2-s2.0-105008378552
Journal Title
Pharmaceutical Sciences Asia
Volume
52
Issue
2
Start Page
240
End Page
249
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Sciences Asia Vol.52 No.2 (2025) , 240-249
Suggested Citation
Maneerojpakdee D., Natapulwat N., Sinchaipanid N. Soybean Oil in Nifedipine-Loaded Nanostructured Lipid Carriers: Enhancing Drug Loading and Release. Pharmaceutical Sciences Asia Vol.52 No.2 (2025) , 240-249. 249. doi:10.29090/psa.2025.02.24.2601 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110936
Title
Soybean Oil in Nifedipine-Loaded Nanostructured Lipid Carriers: Enhancing Drug Loading and Release
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Nanostructured lipid carriers (NLCs) are widely recognized for their ability to improve drug loading (DL) capacity and release characteristics for poorly water-soluble drugs. In this study, nifedipine-loaded NLCs (NLC-NIs) were prepared using an ultrasonic emulsification method. The effects of dispersion energy and sonication time on the optimization of the preparation process were systematically investigated. The influence of soybean oil (SO) content, ranging from 5% to 25% w/w of the total lipid, on the physicochemical properties, entrapment efficiency (EE), and drug loading capacity (DL) was evaluated and compared with nifedipine-loaded solid lipid nanoparticles (SLN-NI). Results indicated that both %EE and %DL increased with higher SO concentrations. At the highest SO content, EE and DL were achieved at 97.66% ± 0.06 and 19.52% ± 0.01, respectively, while SLN-NI exhibited significantly different (p < 0.05) lower EE and DL values of 41.63% ± 0.10 and 8.32% ± 0.01, respectively. The particle size of NLC-NI 5 was 281.9 ± 16.4 nm, which was slightly larger with significantly different (p < 0.05) than that of SLN-NI (220.3 ± 14.5 nm). Additionally, NLC-NI demonstrated a superior sustained release profile in vitro compared to SLN-NI. In conclusion, the incorporation of SO in NLC formulations markedly improved drug EE, DL, and sustained release characteristics compared to solid lipid nanoparticles.